Overview and Scope
RNA-targeting small molecule therapeutics refers to small molecule therapeutics that precisely interact with RNA molecules to modify their function or stability. These treatments treat diseases by employing small-molecule drugs to target disease-causing RNA molecules.
Sizing and Forecast
The rna targeting small molecules therapeutics market size has grown exponentially in recent years. It will grow from $1.06 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 37.0%. The growth in the historic period can be attributed to drug discovery and development, rising prevalence of rna-related diseases, government and private funding, pharmaceutical industry interest, rna therapeutics success stories.
The rna targeting small molecules therapeutics market size is expected to see exponential growth in the next few years. It will grow to $5.09 billion in 2028 at a compound annual growth rate (CAGR) of 36.9%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, rise in rna biomarker identification, expanding rna target spectrum, increasing funding and investments, application in rare diseases. Major trends in the forecast period include advancements in screening technologies, antisense oligonucleotides dominance, small molecule rna binders, rna therapeutics in neurological disorders, gene editing with crispr-cas9.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report
Segmentation & Regional Insights
The rna targeting small molecules therapeutics market covered in this report is segmented –
1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users
North America was the largest region in the RNA targeting small molecules therapeutics market in 2023. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp
Major Driver Impacting Market Growth
The increasing number of cancer cases is expected to propel the growth of the RNA-targeting small molecule therapeutics market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Cancer is treated with RNA-targeting small molecules created and investigated to target RNA molecules associated with cancer selectively. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, in the US, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in 2022. It is about 1,670 fatalities each day. Therefore, the increasing number of cancer cases is driving the growth of the RNA-targeting small molecule therapeutics market.
Key Industry Players
Major companies operating in the rna targeting small molecules therapeutics market report are F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Celgene Corporation, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics.
The rna targeting small molecules therapeutics market report table of contents includes:
1. Executive Summary
2. RNA Targeting Small Molecules Therapeutics Market Characteristics
3. RNA Targeting Small Molecules Therapeutics Market Trends And Strategies
4. RNA Targeting Small Molecules Therapeutics Market – Macro Economic Scenario
5. Global RNA Targeting Small Molecules Therapeutics Market Size and Growth
.
.
.
32. Global RNA Targeting Small Molecules Therapeutics Market Competitive Benchmarking
33. Global RNA Targeting Small Molecules Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The RNA Targeting Small Molecules Therapeutics Market
35. RNA Targeting Small Molecules Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
